Home > Healthcare & Medical Devices > Prurigo Nodularis Treatment Market

Prurigo Nodularis Treatment Market Size By Product (Antihistamines, Capsaicin Cream, Corticosteroids, Emollients), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), Regional Outlook, Industry Analysis Report, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032

  • Report ID: GMI3849
  • Published Date: Dec 2022
  • Report Format: PDF

Industry Overview

Prurigo Nodularis Treatment Market size crossed USD 2 billion in 2022 and is slated to depict a 4% CAGR from 2023 to 2032.
 

The consistent expansion of the pharmaceutical and biotechnology industry globally is among the leading factors spurring the demand for prurigo nodularis treatment. The consistently expanding geriatric population base and the subsequent rise in the burden of chronic diseases have encouraged pharmaceutical manufacturers worldwide to make significant R&D investments and develop novel antibiotics, treatments, and vaccines.
 

Prurigo Nodularis Treatment Market

Get more details on this report - Request Free Sample PDF
 

Besides, the ongoing advancements focused on fulfilling the healthcare requirements of people living in emerging economies are likely to offer an anticipated boost to the pharmaceutical sector.
 

Limited treatment options may restrict industry progress

Prurigo nodularis is an underdiagnosed disease requiring an extensive range of topical steroids to contain the spread of the disease. However, at present, only a limited number of target therapies are available in the market to treat the condition. Therefore, the lack of approved drugs or targeted therapies may restrict industry expansion.
 

Corticosteroids to emerge as preferred treatment choice due to their ability to relieve disease symptoms

Prurigo Nodularis Treatment Market by Product

Get more details on this report - Request Free Sample PDF

 

Prurigo nodularis treatment market from the corticosteroids segment is set to amass more than 35.5% business share by 2032. The increasing usage of corticosteroids in the treatment of the given health condition will primarily support segment landscape. Drugs containing corticosteroids help lower bodily inflammation and minimize the occurrence of itching, swelling, and redness. Given these exceptional attributes, corticosteroids are considered a preferred treatment choice for patients with prurigo nodularis, which will drive segmental revenues.
 

Wide range of product availability to aid the proliferation of retail pharmacies as a leading distribution channel

Prurigo Nodularis Treatment Market by Distribution Channel

Get more details on this report - Request Free Sample PDF
 

Prurigo nodularis treatment market from the prurigo nodularis treatment industry segregates into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment garnered over USD 800 million in 2022. The increasing prevalence of prurigo nodularis has resulted in an elevated demand for a variety of medications, ointments, lotions, and other goods associated with the disease treatment. Retail stores are easily accessible and offer a range of these medications at affordable prices, which may bolster their sales in the foreseeable future.
 

Expanding the elderly population to create new growth prospects for the prurigo nodularis treatment industry across North America

Prurigo Nodularis Treatment Market by Region

Get more details on this report - Request Free Sample PDF
 

North America prurigo nodularis treatment market held a substantial revenue share over 40% in 2022, backed by the consistent expansion of the aging populace. For instance, the elderly population globally is estimated to grow double fold and cross 1.5 billion by 2050. The greater susceptibility of the elderly to several illnesses may result in increased incidences of prurigo nodularis, which will boost product adoption across North America.
 

New product developments to boost the competitive landscape

Major firms having a strong presence in the prurigo nodularis market are Teva Pharmaceutical Industries Ltd, Pfizer Inc., Sanofi, GlaxoSmithKline plc., Merck & Co. Inc., Bayer AG, Johnson & Johnson Services Inc., Galderma, and Takeda Pharmaceuticals. Companies operating in this vertical are emphasizing developing novel treatment options for patients suffering from the given skin condition and making a mark in the healthcare sector.
 

Impact of COVID-19 on the Prurigo nodularis treatment market trends

The onset of the global health calamity COVID-19 disrupted industry value chains across the globe and took a huge toll on the global healthcare sector. However, the prurigo nodularis treatment industry stayed quite unaffected by the disruption caused during the crisis. The disease is an autoimmune disorder, and only a few patients witnessed elevated symptoms due to the viral outbreak. Additionally, market players, governments, and non-government organizations across several economies undertook necessary initiatives to generate disease awareness and introduce novel preventive and target therapies and treatments, further expanding the market share.
 

The Prurigo nodularis treatment market report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032 for the following segments:

By Product

  • Antihistamines
  • Capsaicin Cream
  • Corticosteroids
  • Emollients
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Others

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Global market for prurigo nodularis treatment garnered over USD 2 billion in 2022 and is poised to witness a 4% CAGR from 2023 to 2032 owing to the flourishing biotechnology and pharmaceutical sectors globally.

Corticosteroids segment is anticipated to accumulate more than 35.5% market share by 2032 due to the proven efficacy of corticosteroids in relieving the symptoms of prurigo nodularis.

Prurigo nodularis treatment market from the retail pharmacies segment amassed over USD 800 million in 2022 attributed to the increasing disease prevalence and wide range availability of a variety of medications at competitive prices.

Teva Pharmaceutical Industries Ltd, Pfizer Inc., Sanofi, GlaxoSmithKline plc., Merck & Co. Inc., Bayer AG, Johnson & Johnson Services Inc., Galderma, and Takeda Pharmaceuticals are the prominent companies operating in the market.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 126
  • Countries covered: 15
  • Pages: 105

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount